Optibiotix Health Share Discussion Threads

[shrewdmole] 20/2/2019 19:27

Parob

Have you got the $10bn turnover global dairy company on there?

S

[imnotlong] 20/2/2019 19:15

Rayrac, even I think it’s only a matter of time before it all comes good.

And that time is not too far off.

Maybe then you might retire gracefully, as I intend to as well.

[parob] 20/2/2019 19:13

A reminder whilst we wait for the next deal.Recent, current and potential future revenue streams confirmed:- GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance)- Sacco/CSL - HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical)- Pharmabiota- Galenicum Special Ingredients - Knighton Foods- Cereal Ingredients Inc.- Fine Foods & Pharmaceuticals- Trigen Pharma- Cambridge Commodities - Akums Drugs and Pharma- Seed Health- John Morley's - Alfasigma- Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution.- Unnamed US pharma partner (cholesterol strain)- Bened Biomedical- Bulgarian CholBiome distributor (Velinoff Pharma)- CTC Group- Formulation Creations- US Pharma Lab Inc.- Unnamed Greece and Cyprus CholBiome distributor- Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences - SilvExpo - CholBiome- Biolat - RMS CardioPro- EIWA Trading Co. LtdRevenue not confirmed yet:- Tata X 2 (Slimbiome and LPGOS)- Mystery US Slimbiome customer- Paradise Fruits (Slimbiome)- Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL)Products on the market already but not RNSed:- MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic - Aragan - Biotic•P3- 39ytu - Capsa Food

[rayrac] 20/2/2019 19:09

Clinical study carried out by the University of Roehampton and supported and paid for by OptiBiotix.....?

Still waiting for a deal to become a contract and cash to hit the bottom line!

[toyin] 20/2/2019 19:05

RK, I gave you the benefit of the doubt. Sorry folks you were right I was wrong, he/she is a prat!

[imnotlong] 20/2/2019 18:30

Thought you had been asked not to do these votes.....

[reckless kelly] 20/2/2019 18:22

Absolutely, what a super exciting company this is to hold shares in.

1) If you agree with this post and can't get enough of these shares please vote down.
2) If you're so excited & think the shares will double in no time this year, vote up.

[parob] 20/2/2019 18:18

Missed this earlier. SlimBiome also reduces blood pressure!

Slimbiome(R): Clinic Impact of SlimBiome(â) on satiety, satiation, weight loss and gut microbiome composition in overweight and obese women
This abstract presented the results of an independent clinical study carried out by the University of Roehampton which demonstrated that human volunteers taking SlimBiome(R) had STATISTICALLY SIGNIFICANT REDUCTIONS in weight, BMI, hip circumference, percentage body fat, fat mass and SYSTOLIC BLOOD PRESSURE (P<0.01) after four weeks of SlimBiome(â) intake.

[nobbygnome] 20/2/2019 18:17

>> belgrano

LOL. I gave that a 👍

[shrewdmole] 20/2/2019 18:00

Lol!!

In all seriousness though what a usp

[belgrano2] 20/2/2019 17:16

brilliant to see that taking slimbione improves mood.
Now got to force feed the misses.

[2350220] 20/2/2019 10:51

Shall I delete it now JJ?
Don't like choking up the board Unnecessarily.
John

[judijudi] 20/2/2019 10:29

Hi John,
Hope your well
Thanks for that Mate
I read the RNS at 7am on Investegate but it’s not showing as released on my advfn monitor

[rayrac] 20/2/2019 10:16

Here are the series of Per’s 5 tweets for those without access to twitter:.....

So it comes down a one man trial now...from a director no less. Ffs!

More...

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased with the high amount of scientific and commercial interest in our presentations at ProBiota which demonstrated the breadth of our scientific development. These studies, and the publications and presentations from them presented at internationally renowned events, are part of a strategy of developing microbiome products with a strong scientific and clinical evidence base with key opinion leader support. This provides clear product differentiation which can be translated into evidenced based product consumer claims. This attracts commercial interest in our technology...

Prove it through phase 1/2/3 trials and nhs approval!

[2350220] 20/2/2019 10:05

Here you go Judy Judy
20 February 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Presentations at ProBiota - 2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces its three abstracts at the ProBiota 2019 event between 13-15 February 2019, at Scandic Copenhagen, Denmark.

ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned meeting place for a community of scientists and industry leaders who want to translate the latest science into new products in the growing supplements and ingredients market. The three abstracts presented were as follows: -

SweetBiotix(R): Sweet fibres with a microbiome modulating effect

Optibiotix has a number of development programmes creating natural sweet fibres (SweetBiotix(R)) with the potential to meet the needs of both the natural high intensity sweetener and bulk sugar markets. These markets are collectively forecast to reach $112bn by 2022 (Mordor Intelligence, 2017). The abstract presented at ProBiota reported on human studies from an expert panel of 12 flavourists of its natural high intensity sweeteners. These showed high sweetness, reduced bitterness and reduced off-flavours when compared to natural sweeteners like Stevia. The products were then tested for their ability to modify microbiome composition and activity in healthy adults. The results showed significant increases in short-chain fatty acids ("SCFA"), the molecular messengers produced by bacteria when they ferment fibre and non-digestible carbohydrates. SCFA are widely known for their importance in gut health, immunity and affect how energy is metabolised in the body, and are one of the main ways in which the gut microbiome contributes to better health. Whilst previous studies (RNS: 23 January 2018) have demonstrated that these fibres have high sweetness and no aftertaste, this is the first study to demonstrate a positive effect on the microbiome. This creates a clear differentiator to other sweeteners on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right. The results were well received and will be used by OptiBiotix as leverage in existing and future commercial discussions to optimise shareholder value.

Slimbiome(R): Clinic Impact of SlimBiome(â) on satiety, satiation, weight loss and gut microbiome composition in overweight and obese women

This abstract presented the results of an independent clinical study carried out by the University of Roehampton which demonstrated that human volunteers taking SlimBiome(R) had statistically significant reductions in weight, BMI, hip circumference, percentage body fat, fat mass and systolic blood pressure (P<0.01) after four weeks of SlimBiome(â) intake. Significant reduction in cravings for savoury foods (P<0.001) and a trend for reduced sweet cravings were recorded from the end of week one of the treatment onwards, accompanied by a significant improvement in mood (P<0.01). Notable increases were observed in the relative abundance of Christensenellaceae, Bacteroidetes and Actinobacteria. These are bacteria within the gut microbiome which other studies have associated with weight loss and leaner body types. This study adds further evidence to other clinical studies and consumer feedback which shows SlimBiome(â) has a significant impact on food cravings and hunger, leading to easier and more successful weight loss, typically 2-3lbs per week. The increase in bacteria within the gut associated with weight loss in people taking SlimBiome(R) is an exciting development and will be the subject of further studies.

Antimicrobial activity of Lactobacillius Plantarum LP(LDL) (R)OptiBiotix presented research on the antimicrobial activity of L. plantarum LP(LDL) (R) pregrown on different carbohydrates, against a selection of pathogens of clinical relevance. LP(LDL) (R) has an established cholesterol reducing activity in normal to mildly hypercholesterolaemic (high cholesterol levels) adults. The studies, carried out by the University of Reading, showed LP(LDL) (R) demonstrated antimicrobial activity against a wide range of clinically important clinical pathogens including those known to cause serious gastrointestinal infections around the world. These include Campylobacter, Shigella, Salmonella, E.coli O157, and significantly Clostridium difficile, the cause of serious hospital acquired infections. The results of this study suggest LP(LDL) (R) may have additional biological activities which if proven in human studies, have the potential to widen LP(LDL) (R)'s commercial opportunities to include gut health and the prevention of traveller's diarrhoea. This will help support the use of LP(LDL) (R) in a wide range of food, dairy, supplement and biopharmaceutical products. This research gives an early indication as to LP(LDL) (R)'s potential to extend its existing use as a supplement into a wide range of consumer food and healthcare products.

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased with the high amount of scientific and commercial interest in our presentations at ProBiota which demonstrated the breadth of our scientific development. These studies, and the publications and presentations from them presented at internationally renowned events, are part of a strategy of developing microbiome products with a strong scientific and clinical evidence base with key opinion leader support. This provides clear product differentiation which can be translated into evidenced based product consumer claims. This attracts commercial interest in our technology and products leading to a healthy deal pipeline. As we continue to build the science around existing products and platforms and identify new application opportunities; the scale of the opportunity, and the potential value of OptiBiotix, increases."

[judijudi] 20/2/2019 09:56

The RNS still not showing on my advfn stock monitor

[diamond fibre] 20/2/2019 08:33

I have said before we have loads more to come. DIAMOND.

[woodaldo] 20/2/2019 08:30

That RNS has actually amazing snippets of info in there. To see that all 3 of our current products go beyond what they originally were planned for is great news, it adds further weight to our products, making them stand head and shoulders over our competition. Impressed that Sweetbiotix significantly increases short-chain fatty acids. A sugar that makes you healthier with less aftertaste than Stevia. That's actually staggering. Also to see the anti-microbial properties in LPLDL is really significant. What else might these products do as further studies are completed. The microbiome potentially could be one of the hugely significant advances in science of our times, and opti are at the forefront leading us there. Its nice to be invested in something that could get us significantly wealthier but significantly healthier too.

[shrewdmole] 20/2/2019 08:28

I’m more into reading the mm and every small buy is moving them.
Fincap on the bid usually a positive sign.

[scotty1] 20/2/2019 08:25

Nobby whys that then a 9k sell in SBTX wouldn't give enough funds to buy 9k in OPTI

edit
apologies yep got you now

[nobbygnome] 20/2/2019 08:21

Someone just switched funds from SBTX to OPTI it seems to me.... a £9k sell in SBTX followed by a £9k buy in OPTI....

[scotty1] 20/2/2019 08:21

Paying over.which is nice.tick up coming

[primal123] 20/2/2019 08:19

The opportunity here is outstanding!